Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Exchange Rates
Interest Rates
Futures
Economy
Global Metrics

BioCryst Pharmaceuticals Shares Outstanding 2006-2020 | BCRX

BioCryst Pharmaceuticals shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
BioCryst Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2019 116
2018 103
2017 84
2016 74
2015 73
2014 67
2013 55
2012 49
2011 45
2010 45
2009 39
2008 38
2007 33
2006 29
2005 26
BioCryst Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2020-09-30 177
2020-06-30 162
2020-03-31 154
2019-12-31 116
2019-09-30 110
2019-06-30 110
2019-03-31 110
2018-12-31 103
2018-09-30 105
2018-06-30 99
2018-03-31 99
2017-12-31 84
2017-09-30 84
2017-06-30 80
2017-03-31 75
2016-12-31 74
2016-09-30 74
2016-06-30 74
2016-03-31 74
2015-12-31 73
2015-09-30 73
2015-06-30 77
2015-03-31 72
2014-12-31 67
2014-09-30 72
2014-06-30 64
2014-03-31 60
2013-12-31 55
2013-09-30 57
2013-06-30 53
2013-03-31 51
2012-12-31 49
2012-09-30 51
2012-06-30 49
2012-03-31 47
2011-12-31 45
2011-09-30 45
2011-06-30 45
2011-03-31 45
2010-12-31 45
2010-09-30 45
2010-06-30 45
2010-03-31 44
2009-12-31 39
2009-09-30 38
2009-06-30 38
2009-03-31 38
2008-12-31 38
2008-09-30 38
2008-06-30 38
2008-03-31 38
2007-12-31 33
2007-09-30 34
2007-06-30 29
2007-03-31 29
2006-12-31 29
2006-09-30 29
2006-06-30 29
2006-03-31 29
2005-12-31 26
2005-09-30 26
2005-06-30 26
2005-03-31 24
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.554B $0.049B
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.784B 41.85
Takeda Pharmaceutical (TAK) Japan $54.984B 10.26
Astellas Pharma (ALPMY) Japan $29.565B 18.47
Eisai (ESALY) Japan $22.210B 19.35
Catalent (CTLT) United States $19.023B 56.90
Grifols, S.A (GRFS) Spain $13.118B 15.02
Neurocrine Biosciences (NBIX) United States $10.061B 79.18
Jazz Pharmaceuticals (JAZZ) Ireland $9.344B 15.10
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $8.578B 0.00
Ionis Pharmaceuticals (IONS) United States $8.568B 83.95
Arrowhead Pharmaceuticals (ARWR) United States $8.297B 0.00
United Therapeutics (UTHR) United States $7.680B 16.35
IPSEN SA ADR (IPSEY) France $7.218B 0.00
Orion OYJ (ORINY) Finland $6.427B 22.30
Evotec AG (EVTCY) Germany $5.819B 394.44
Sage Therapeutics (SAGE) United States $4.756B 0.00
PTC Therapeutics (PTCT) United States $4.673B 0.00
Hypermarcas (HYPMY) Brazil $4.415B 16.21
ChemoCentryx (CCXI) United States $4.292B 0.00
FibroGen (FGEN) United States $3.934B 0.00
Cronos Group (CRON) Canada $3.889B 0.00
Corcept Therapeutics (CORT) United States $3.269B 31.62
Pacira BioSciences (PCRX) United States $3.201B 69.51
Nektar Therapeutics (NKTR) United States $3.046B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.972B 15.17
Xencor (XNCR) United States $2.784B 0.00
Revolution Medicines (RVMD) United States $2.706B 0.00
Tilray (TLRY) Canada $2.630B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.766B 15.11
Translate Bio (TBIO) United States $1.734B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.685B 0.00
USANA Health Sciences (USNA) United States $1.669B 14.69
Endo (ENDP) Ireland $1.640B 2.49
Heron Therapeutics (HRTX) United States $1.603B 0.00
Ocular Therapeutix (OCUL) United States $1.542B 0.00
Trillium Therapeutics (TRIL) Canada $1.470B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.448B 10.06
ImmunoGen (IMGN) United States $1.404B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.151B 0.00
Indivior (INVVY) United States $1.139B 0.00
Karyopharm Therapeutics (KPTI) United States $1.100B 0.00
Zogenix (ZGNX) United States $1.038B 0.00
ORGANOGENESIS (ORGO) United States $1.024B 0.00
Radius Health (RDUS) United States $1.012B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.942B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.938B 0.00
Vectura Group (VEGPF) United Kingdom $0.925B 0.00
Collegium Pharmaceutical (COLL) United States $0.832B 49.10
VAXART, INC (VXRT) United States $0.786B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.721B 0.00
Esperion Therapeutics (ESPR) United States $0.712B 0.00
Acutus Medical (AFIB) United States $0.659B 0.00
Aerie Pharmaceuticals (AERI) United States $0.653B 0.00
Flexion Therapeutics (FLXN) United States $0.644B 0.00
Chinook Therapeutics (KDNY) United States $0.641B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.635B 0.00
Ardelyx (ARDX) United States $0.615B 0.00
Harpoon Therapeutics (HARP) United States $0.594B 0.00
Siga Technologies (SIGA) United States $0.563B 15.80
Molecular Templates (MTEM) United States $0.552B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.524B 0.00
Sundial Growers (SNDL) Canada $0.504B 0.00
PROFOUND MEDICL (PROF) Canada $0.491B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.468B 0.00
Akebia Therapeutics (AKBA) United States $0.441B 0.00
Summit Therapeutics (SMMT) United States $0.438B 0.00
Altimmune (ALT) United States $0.428B 0.00
CASI Pharmaceuticals (CASI) United States $0.420B 0.00
TherapeuticsMD (TXMD) United States $0.414B 0.00
DURECT (DRRX) United States $0.412B 0.00
Rafael Holdings (RFL) United States $0.400B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.389B 0.00
Innate Pharma SA (IPHYF) France $0.371B 0.00
Jounce Therapeutics (JNCE) United States $0.363B 0.00
Concert Pharmaceuticals (CNCE) United States $0.363B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.362B 9.43
MEI Pharma (MEIP) United States $0.320B 0.00
Alpine Immune Sciences (ALPN) United States $0.313B 0.00
KalVista Pharmaceuticals (KALV) United States $0.312B 0.00
Nature's Sunshine Products (NATR) United States $0.304B 19.59
Menlo Therapeutics (VYNE) United States $0.280B 0.00
Lannett Co Inc (LCI) United States $0.279B 7.36
Redhill Biopharma (RDHL) Israel $0.278B 0.00
Jaguar Animal Health (JAGX) United States $0.266B 0.00
Xeris Pharmaceuticals (XERS) United States $0.263B 0.00
Aclaris Therapeutics (ACRS) United States $0.252B 0.00
Otonomy (OTIC) United States $0.251B 0.00
CTI BioPharma (CTIC) United States $0.245B 0.00
IMV INC (IMV) Canada $0.237B 0.00
Calithera Biosciences (CALA) United States $0.235B 0.00
OptiNose (OPTN) United States $0.218B 0.00
Oncternal Therapeutics (ONCT) United States $0.213B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.209B 0.00
Infinity Pharmaceuticals (INFI) United States $0.204B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.188B 0.00
ProPhase Labs (PRPH) United States $0.186B 0.00
Novan (NOVN) United States $0.180B 0.00
Aquestive Therapeutics (AQST) United States $0.179B 0.00
Onconova Therapeutics (ONTX) United States $0.172B 0.00
Taiwan Liposome (TLC) Taiwan $0.166B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.166B 0.00
Ayala Pharmaceuticals (AYLA) Israel $0.165B 0.00
Champions Oncology (CSBR) United States $0.150B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.146B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.146B 0.00
Heat Biologics (HTBX) United States $0.145B 0.00
MediWound (MDWD) Israel $0.137B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.113B 0.00
Lipocine (LPCN) United States $0.106B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.099B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.094B 0.00
SCYNEXIS (SCYX) United States $0.086B 0.00
Natural Alternatives (NAII) United States $0.082B 158.75
ElectroCore (ECOR) United States $0.080B 0.00
Nutriband (NTRB) United States $0.077B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.076B 0.00
Recro Pharma (REPH) United States $0.070B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.070B 0.00
Biomerica (BMRA) United States $0.067B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.063B 0.00
CV Sciences (CVSI) United States $0.063B 0.00
Iterum Therapeutics (ITRM) Ireland $0.059B 0.00
Vical (BBI) United States $0.059B 0.00
Addex Therapeutics (ADXN) Switzerland $0.059B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.054B 0.00
RENEURON GP (RNUGF) United Kingdom $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.049B 24.96
Regulus Therapeutics (RGLS) United States $0.047B 0.00
PolarityTE (PTE) United States $0.042B 0.00
Neos Therapeutics (NEOS) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.038B 5.56
Opiant Pharmaceuticals (OPNT) United States $0.037B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.029B 0.00
Midatech Pharma (MTP) United Kingdom $0.029B 0.00
KemPharm (KMPH) United States $0.026B 0.00
Flex Pharma (SLRX) United States $0.024B 0.00
China SXT Pharmaceuticals (SXTC) China $0.020B 0.00
Cyanotech (CYAN) United States $0.019B 31.90
HANCOCK JAFFE (HJLI) United States $0.019B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.018B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.017B 0.00
Xenetic Biosciences (XBIO) United States $0.017B 0.00
RXi Pharmaceuticals (PHIO) United States $0.017B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.011B 0.00
Shineco (TYHT) China $0.011B 0.00
JanOne (JAN) United States $0.010B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00